Ionis Pharmaceuticals has received a significant boost in its neurology pipeline with the U.S. Food and Drug Administration granting Breakthrough Therapy designation to zilganersen, the company’s investigational treatment for Alexander disease (AxD). The rare and devastating neurological disorder currently has no approved disease-modifying therapies, making the FDA’s decision an important step toward addressing a long-standing unmet medical need.
Alexander disease is a progressive neurodegenerative condition that affects both children and adults. It is characterized by the accumulation of abnormal proteins in the central nervous system, leading to severe symptoms such as loss of mobility, difficulties with walking, speaking, swallowing and, in advanced stages, respiratory compromise. Many patients experience a rapid decline, and the disorder is often fatal. Given the seriousness and lack of effective treatment options, Breakthrough Therapy designation offers an expedited review pathway for therapies that show strong preliminary evidence of substantial clinical benefit.
Ionis’ senior vice president of neurology, Holly Kordasiewicz, Ph.D., said the designation underscores the importance of the company’s work in developing a therapy capable of altering the course of AxD. “People living with Alexander disease have gone far too long without a treatment capable of changing the course of their disease,” she said. “Our pivotal study provides the first evidence that an investigational therapy can modify the underlying disease and improve outcomes. We are deeply grateful to the individuals, families and investigators who made this progress possible.”
The FDA’s decision was supported by compelling topline data from the pivotal clinical trial evaluating zilganersen in both pediatric and adult patients. Treatment with zilganersen 50 mg demonstrated statistically significant and clinically meaningful stabilization of gait speed—measured by the 10-Meter Walk Test—over 61 weeks. Patients receiving the drug achieved a 33.3% improvement compared with the control group (p=0.0412). Ionis reported that the therapy was well tolerated, with a favorable safety profile, and that benefits were consistently observed across key secondary endpoints.
The designation marks Ionis’ second Breakthrough Therapy recognition in quick succession, following the FDA’s decision to grant the status to olezarsen for severe hypertriglyceridemia. According to Brett Monia, Ph.D., chief executive officer of Ionis, these back-to-back achievements highlight the strength of the company’s innovation and the depth of its expanding late-stage pipeline. “We look forward to independently bringing both these medicines to patients in 2026,” he said. “The combination of marketed medicines and our exceptional pipeline positions Ionis for accelerating revenue growth and substantial value creation.”
Ionis plans to submit a New Drug Application for zilganersen in the first quarter of 2026. The company is also working to initiate an Expanded Access Program in the United States, which would allow eligible patients with urgent medical needs to receive the therapy while the FDA completes its formal review.
For the Alexander disease community—patients, caregivers and physicians alike—the Breakthrough Therapy designation represents a long-awaited step toward the first potential treatment capable of modifying the disease rather than simply managing symptoms. As Ionis prepares its regulatory filings and expands access pathways, hopes are rising that zilganersen could soon become the first approved therapy to change the trajectory of this devastating disorder.